Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4754

Sort by

Sort Order Select

Journal Articles

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Fieke W. Hoff, Anneke D. van Dijk, Yihua Qiu, Peter P. Ruvolo, Robert B. Gerbing, Amanda R. Leonti, Gaye N. Jenkins, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Eveline S. J. M. de Bont, Sophia W. M. Bruggeman, Steven M. Kornblau, Terzah M. Horton

Blood (2021) 137 (8): 1050–1060.

https://doi.org/10.1182/blood.2020005208

Published: 2021

Includes: Supplemental data

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (25): 2271–2280.

https://doi.org/10.1182/blood.2019000834

Published: 2019

Journal Articles

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma

Boheng Li, Junli Yan, The Phyu, Shuangyi Fan, Tae-Hoon Chung, Nurulhuda Mustafa, Baohong Lin, Lingzhi Wang, Pieter Johan Adam Eichhorn, Boon-Cher Goh, Siok-Bian Ng, Dennis Kappei, Wee-Joo Chng

Blood (2019) 134 (23): 2046–2058.

https://doi.org/10.1182/blood.2019000381

Published: 2019

Includes: Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Curcumin Enhances the Sensitivity of Bortezomib By Inhibiting NF-Κb in ABC Diffuse Large B-Cell Lymphoma Cells

Xiaolei Wei, PhD, Jialin Song, Yongqiang Wei, PhD, Hong Zeng, Weimin Huang, PhD, Jingxia Zheng, Ru Feng, MD

Blood (2019) 134 (Supplement_1): 5237.

https://doi.org/10.1182/blood-2019-127705

Published: 2019

Journal Articles

Gastrointestinal Plasmoblastic Lymphoma Associated with Wiskott-Aldrich Syndrome: A Case Report

Ali Unal, MD, Serhat Çelik, Zeynep Güven, MD, Leylagul Kaynar, MD, Bulent Eser, MD, Mustafa Çetin

Blood (2019) 134 (Supplement_1): 5359.

https://doi.org/10.1182/blood-2019-123387

Published: 2019

Journal Articles

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Oren Pasvolsky, MD, Alon Rozental, MD, Pia Raanani, MD, Anat Gafter-Gvili, MD, Ronit Gurion

Blood (2019) 134 (Supplement_1): 5331.

https://doi.org/10.1182/blood-2019-126013

Published: 2019

Journal Articles

Real-World Practice Patterns in a Nationwide Cohort of Veterans with Waldenström's Macroglobulinemia

Kelli M Rasmussen, MS, Vikas Patil, MS, Hsu-Chih Chien, PhD MSc, Deborah Kay Morreall, BS, Catherine Li, PhD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 5270.

https://doi.org/10.1182/blood-2019-127738

Published: 2019

Journal Articles

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Agrima Mian, MBBS, MD, Albert Aboseif, DO, Wei Wei, MS, Rajshekhar Chakraborty, MD, Jack Khouri, MD, Joslyn Rudoni, PharmD, Allison M. Winter, MD, Sonam Patel, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Brad Pohlman, MD, Stephanie Berg, DO, James R. Cook, MD PhD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD

Blood (2019) 134 (Supplement_1): 5248.

https://doi.org/10.1182/blood-2019-130396

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Retrospective Review of Patients with Large Granular Lymphocyte (LGL) Leukemia in a Single Institution over a Period of 11 Years

Kulsum Bano, MD, Manojna Konda, MD, Dinesh Atwal, MD, Richa Parikh, MD, Aneesha Ananthula, MD, Anusha Jillella, MD, Aasiya Matin, MD, Appalanaidu Sasapu, MD

Blood (2019) 134 (Supplement_1): 5279.

https://doi.org/10.1182/blood-2019-131352

Published: 2019

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Naomi Aoki, MSc, BSc, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Zoe McQuilten, Cameron Wellard, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2019) 134 (Supplement_1): 5518.

https://doi.org/10.1182/blood-2019-124256

Published: 2019

Journal Articles

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Nicola Giuliani, Silvia Valtorta, PhD, Martina Chiu, PhD, Denise Toscani, PhD, Andrea Sartori, PhD, Angela Coliva, PhD, Arianna Brevi, Stefania Battaglia, MS, Emanuela Vicario, PhD, Giuseppe Taurino, MS, Matteo Grioni, Francesca Ferlenghi, PhD, Livia Ruffini, MD, Federica Vacondio, PhD, Franca Zanardi, PhD, Matteo Bellone, MD, Rosa Maria Moresco, PhD, Ovidio Bussolati, MD PhD

Blood (2019) 134 (Supplement_1): 5542.

https://doi.org/10.1182/blood-2019-127935

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

https://doi.org/10.1182/blood-2019-125884

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

AL patients don’t dare go without dara

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Curcumin Enhances the Sensitivity of Bortezomib By Inhibiting NF-Κb in ABC Diffuse Large B-Cell Lymphoma Cells

Gastrointestinal Plasmoblastic Lymphoma Associated with Wiskott-Aldrich Syndrome: A Case Report

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Real-World Practice Patterns in a Nationwide Cohort of Veterans with Waldenström's Macroglobulinemia

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Retrospective Review of Patients with Large Granular Lymphocyte (LGL) Leukemia in a Single Institution over a Period of 11 Years

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Email alerts

ASH Publications

American Society of Hematology